BRAINSTORM CELL THERAPUTC
BCLI
BCLI was delisted on the 17th of July, 2025.
48 hedge funds and large institutions have $11M invested in BRAINSTORM CELL THERAPUTC in 2022 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 6 increasing their positions, 17 reducing their positions, and 2 closing their positions.
694% more call options, than puts
Call options by funds: $2.45M | Put options by funds: $308K
450% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 2
23% more funds holding
Funds holding: 39 → 48 (+9)
0.04% less ownership
Funds ownership: 0.76% → 0.73% (-0.04%)
28% less capital invested
Capital invested by funds: $15.3M → $11M (-$4.3M)
65% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LWM
Liberty Wealth Management
Oakland,
California
|
+$90.1K |
| 2 |
VF
Virtu Financial
New York
|
+$62.1K |
| 3 |
Renaissance Technologies
New York
|
+$51.3K |
| 4 |
Jane Street
New York
|
+$36.3K |
| 5 |
SCFS
S.C. Financial Services
Scottsdale,
Arizona
|
+$30.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$238K |
| 2 |
JP Morgan Chase
New York
|
-$178K |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
-$152K |
| 4 |
Millennium Management
New York
|
-$93.8K |
| 5 |
WCG
Weaver Consulting Group
Huntington Beach,
California
|
-$76.1K |
BCLI Hedge Fund Activity: Q2 2022 in Review
48 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q2 2022, worth a combined $11M — down 28% from $15.3M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new BCLI positions and 2 closed out — a net gain of 9 holders — while 6 added to existing stakes and 17 trimmed.
The largest buyer was Liberty Wealth Management, opening a new position worth an estimated $90.1K. The largest seller was Susquehanna International Group, cutting an estimated $238K.
- 48 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q2 2022, up from 39 in Q1 2022.
- Funds reported $11M of BRAINSTORM CELL THERAPUTC stock for Q2 2022, down 28% quarter-over-quarter.
- 11 funds opened new BRAINSTORM CELL THERAPUTC positions in Q2 2022 and 2 closed out, a net change of +9 holders.
- The largest BRAINSTORM CELL THERAPUTC buyer in Q2 2022 was Liberty Wealth Management, an estimated $90.1K added.
- The largest BRAINSTORM CELL THERAPUTC seller in Q2 2022 was Susquehanna International Group, an estimated $238K sold.
Based on aggregated 13F filings for Q2 2022.